---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-26-000002"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:48:56.102274+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veracyte prelim Q4 rev $138M-$140M (+16-18% YoY); guides FY26 rev $570M-$582M

## Summary
- FY2025 total revenue $515M-$517M (+16% YoY); testing revenue $491M-$493M.
- Decipher volume +27% to ~102K; Afirma volume +11% to ~67.7K in FY2025.
- Prelim FY2025 adj EBITDA margin >25%; FY2026 margin guided at 25%.
- FY2026 total revenue guidance 10-13% growth ($570M-$582M); testing rev +14-16% ($559M-$569M excl. new tests).
- CEO cites upcoming US launch of Prosigna and TrueMRD as growth catalysts.

## SEC filing metadata
- accession: 0001384101-26-000002
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000002/0001384101-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000002/vcyt-20260111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-26-000002
- JSON: https://secwatch.observer/filing/0001384101-26-000002.json
- Plain text: https://secwatch.observer/filing/0001384101-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.